Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Inventiva S.A.

Inventiva Craters On NASH Safety Scare

An adverse reaction in lanafibranor’s Phase III trial leaves the company even more reliant on the upcoming LEGEND readout. 

Clinical Trials Companies

Scrip Podcast: Biopharma’s Must-Know Early 2024 Catalysts

Crunch time is coming for a handful of companies expecting hugely consequential clinical readouts by the end of Q1 2024.

Clinical Trials Commercial

AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH

Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.

Business Strategies Clinical Trials

Novo Nordisk Has Plans For Semaglutide In NASH Too

With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
  • Other Names / Subsidiaries
    • Inventiva Pharmaceuticals
UsernamePublicRestriction

Register